Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 8, 2009
Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibitionLaurie A Robak, Karthik Venkatesh, Hakjoo Lee, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Mabs|November 6, 2025
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Anneliese Schneider, Inja Waldhauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid TumorsMarina Bacac, Tanja Fauti, Johannes Sam, et al.
Oncoimmunology|April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesChristian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Blood|March 4, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Thomas Hofer, Christine Kuettel, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 4